The National Association of Specialty Pharmacy (NASP) recently announced the launch of their new Student Association of Specialty Pharmacy (SASP) via a segment on the Pharmacy Podcast Network. The show, …
PANTHERx® Specialty Pharmacy announced today that it has entered into a partnership with The Health Plan as a provider of specialty pharmacy medications across multiple therapeutic categories. In addition, PANTHERx® …
PANTHERx® Specialty Pharmacy announced today that it has expanded its preferred partnership with Highmark to include Crysvita™ (burosumab-twza). Crysvita™ (burosumab-twza) is the first FDA-approved therapy to treat adults and children …
PANTHERx® Specialty Pharmacy’s Chairman & CEO, Dr. Gordon J. Vanscoy will be presenting a discussion on specialty pharmacy’s evolving role in rare disorders and orphan drugs at the upcoming 7th …
PANTHERx® Specialty Pharmacy (PANTHERx®), THE Rare Disease Specialty Pharmacy®, announced that it has been selected by Ultragenyx Pharmaceutical, Inc. to distribute Crysvita™ (burosumab-twza), the very first FDA-approved therapy for children …
PANTHERx® Specialty Pharmacy is honored to announce our sponsorship of the Soft Bones International Scientific Meeting to promote education and advocacy for hypophosphatasia (HPP). This meeting will host the thought …
Gene therapy isn’t on the horizon anymore; it’s here. Precision medicine demands a level of personalization that few Specialty Pharmacies are equipped to handle. PANTHERx®’s pure focus on rare and …
PANTHERx® Specialty Pharmacy is pleased to announce that it has received full reaccreditation from URAC, pursuant to Specialty Pharmacy, Version 3.0. This accreditation is a reflection of PANTHERx®’s unwavering commitment …
PANTHERx® Specialty Pharmacy, The Rare Disease SP®, is honored to be the recipient of the 2018 APPA “Specialty Pharmacy of the Year Award” and Chairman & CEO, Dr. Gordon J. …
